Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
about
Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy.Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancerComparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.(18)F Sodium Fluoride PET/CT in Patients with Prostate Cancer: Quantification of Normal Tissues, Benign Degenerative Lesions, and Malignant LesionsMetabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of (18)F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis.Present and future roles of FDG-PET/CT imaging in the management of lung cancer.Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot StudyPrognositc significance of SUVmax on pretreatment 18 F-FDG PET/CT in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy: A meta-analysis.Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients.Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients.Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy.Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy.Comparison of different automated lesion delineation methods for metabolic tumor volume of 18F-FDG PET/CT in patients with stage I lung adenocarcinoma.Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.Radiomics analysis at PET/CT contributes to prognosis of recurrence and survival in lung cancer treated with stereotactic body radiotherapy.FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.18F-FDG PET/CT Volumetric Parameters are Associated with Tumor Grade and Metastasis in Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease.Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC.Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation
P2860
Q33750851-6DF8DDCA-6466-4D81-BACF-C82972F7BEEDQ34468661-EC32C08E-1A71-460C-A1C3-B9A773B0954EQ36382039-D21AF952-2647-4612-8086-4F449C276C9CQ36733087-AC805C0E-3E9C-4446-9908-D178306206FEQ37472654-1273E62B-5448-4209-BD76-8EEEFAAC80A4Q37581964-16D2CAA8-B36D-4DA0-A7C6-100BFFE9EA86Q38798562-B67A2352-E5B2-44E5-9ACB-092A2049849BQ38819166-3B9CBF39-0B21-4F8C-A49E-94B0FCC1CCE7Q38841400-72EC2271-1353-4FE6-9BF3-23D1CBF54B4BQ38925620-CB52757C-AE2A-4EC2-923D-F255930B1A89Q38925887-A2CE327D-56AA-4267-AE65-117A5C9346B9Q39412970-5F482165-3BF3-4D59-9AA6-27790AB76F8EQ40888969-2A2DBBA3-6DA4-4536-94CD-CDBD369EBCA2Q42721856-5D13FFFD-D55D-4C9D-82FC-5F066DB2A149Q47173621-B5BE1EDF-6ABB-40CF-AF49-BB30C573E595Q47227265-10B6D6A7-F27D-4F4B-A8FB-F3CA4312026AQ47553437-8E922BD5-3275-421D-A801-F09C4247EACBQ48794414-7A80638A-56F8-41FA-8588-B5884EBB2DD4Q51736041-43E5BD91-D32A-4680-940B-0536CB4CDF6CQ52886599-8CBEB0C3-DF99-4E45-9F97-DB654DC38DD7Q53026528-FE5AC234-2BCF-4065-90DE-8F46E5BFD853Q53060926-E421F4F3-69FF-48CD-A63D-EA868423C8B6Q56764236-DF74A1E2-7B6C-4D7B-852E-6179F04B7BD2
P2860
Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Volume-based parameters measur ...... ion therapy: prognostic value.
@en
type
label
Volume-based parameters measur ...... ion therapy: prognostic value.
@en
prefLabel
Volume-based parameters measur ...... ion therapy: prognostic value.
@en
P2093
P356
P1433
P1476
Volume-based parameters measur ...... ion therapy: prognostic value.
@en
P2093
Atsushi Nambu
Hiroshi Onishi
Tsutomu Araki
Yoko Satoh
P304
P356
10.1148/RADIOL.13130652
P407
P577
2013-10-28T00:00:00Z